Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile phone: A randomized controlled trial among persons with prediabetes

Permalink
https://escholarship.org/uc/item/07705820

Journal
Journal of Medical Internet Research, 17(10)

Authors
Block, G
Azar, KMJ
Romanelli, RJ
et al.

Publication Date
2015

DOI
10.2196/jmir.4897

Peer reviewed
Diabetes prevention and weight loss with a fully-automated behavioral intervention by email, web and smartphone: A randomized controlled trial among persons with pre-diabetes

Block G, Azar KMJ, (Co-first authors) Romanelli RJ, Block TJ, Hopkins D, Carpenter HA, Dolginsky M, Hudes ML, Palaniappan LP, Block CH.

Affiliations:
Gladys Block, PhD: Turnaround Health
Kristen M.J. Azar, R.N., MSN/MPH: PAMFRI
Robert J. Romanelli, Ph.D., M.P.H.: PAMFRI
Torin J. Block, B.A.: Turnaround Health
Donald Hopkins, M.S.: Turnaround Health
Heather A. Carpenter, B.A.: Turnaround Health
Marina Dolginsky, B.S.: PAMFRI
Mark L. Hudes, PhD: University of California, Berkeley
Latha Palaniappan MD, MS, FAHA, FACE: PAMFRI
Clifford H. Block, PhD: Turnaround Health

Short running title: A fully automated program for pre-diabetes

Corresponding author:
Gladys Block
2634 Le Conte Ave, Berkeley, CA 94709
Phone: 510-301-2984. Fax: 510-704-8996
gblock@berkeley.edu

Abstract word count: 449
Manuscript word count: 6057 including tables, captions, etc.
Tables: n=2
Figures: n=4
Abstract

Background: One-third of United States adults, 86 million people, have pre-diabetes. Two-thirds of adults are overweight or obese, and thus at risk for diabetes and other cardiometabolic complications. Effective and affordable interventions are needed that can reach these 86 million, and others at high risk, to reduce their progression to diagnosed diabetes.


Methods: Alive-PD provided individually-tailored behavioral support for improvements in physical activity, eating habits, and related factors such as weight loss, stress reduction, and sleep. Weekly emails suggested small-step goals, and linked to an individual web page with progress tracking, tools for overcoming barriers, social support through virtual teams, competition, and health information. A smartphone app and automated phone calls provided further support.

The trial randomly assigned 339 persons to the Alive-PD intervention (n=163) or a 6-month wait-list control group (n=176). Participants were eligible if either fasting glucose or hemoglobin A1c (HbA1c) was in the pre-diabetic range. Primary outcome measures were clinic-measured changes in fasting glucose and HbA1c at 6 months. Secondary outcome measures included clinic-measured changes in body weight, body mass index, waist circumference, triglyceride/high-density lipoprotein cholesterol (TG/HDL) ratio, and Framingham 8-year diabetes risk score. Analysis was by intention to treat.

Results: Mean age was 55 years, mean BMI was 31.2 kg/m², and 69% were male. Mean fasting glucose was in the pre-diabetic range (mean 109.9 mg/dl), while the mean HbA1c was 5.6%, in the normal range. In intention-to-treat analyses, Alive-PD participants relative to the Control group achieved significantly greater mean (95% CI) reductions in fasting glucose (-7.36 mg/dl [-7.85, -6.87] vs. -2.19 [-2.64, -1.73], \(P<.0001\)), HbA1c (-0.26% [-0.27, -0.24] vs. -0.18% [-0.19, -0.16], \(P<.0001\)), and body weight (-3.26 kg [-3.26, -3.25] vs. -1.26 kg [-1.27, -1.26], \(P<.0001\)). Reductions in BMI, waist circumference, and TG/HDL were also significantly greater in Alive-PD participants than in the Control group. At six months the Alive-PD group had reduced their Framingham 8-year diabetes risk from 16% to 11%, a significantly (\(P=.0004\)) larger risk reduction than was experienced by the Control group. Participation and retention was good; intervention participants interacted with the online program in a median of 17 of the 24 weeks, and 71% (116 of 163) were still interacting with the program in month 6.

Conclusions: Alive-PD was effective in improving glycemic control, body weight, BMI, waist circumference, TG/HDL ratio and diabetes risk. As a fully automated system, the program has high potential for scalability and could potentially reach many of the 86 million adults in the United States who have pre-diabetes, as well as other at-risk groups such as those with metabolic syndrome and obesity.
Trial ID: Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics, clinicaltrials.gov, NCT01479062, https://clinicaltrials.gov/ct2/show/NCT01479062

keywords: Type 2 diabetes, prevention, intervention studies, prediabetes, behavior change, obesity, physical activity, nutrition, internet, smartphone, weight loss
Introduction

In the United States (U.S.), 86 million adults have pre-diabetes [1], a condition characterized by elevated blood glucose that is not yet high enough to be diagnosed as diabetes. Chronic elevated blood glucose levels tend to increase over time, and it is estimated that as many as 70% of those with pre-diabetes will eventually progress to type 2 diabetes [2]. The economic burden of the combined costs of diabetes and pre-diabetes exceeded $322 billion in 2012, and accounted for one in 10 U.S. health care dollars [3]. In an editorial, Cefalu et al. noted that “Increased prevalence, not increased cost per patient, is the driving force behind the increased economic burden of diabetes” [4]. Unless changes are made to prevent progression to type 2 diabetes, costs relating to diabetes management and care will continue to rise at alarming rates. It is critical to develop affordable and effective interventions that can reach more of the 86 million with pre-diabetes with programs to improve glycemic control.

Lifestyle modification has been shown to reduce risk of progression to diabetes by as much as 40-70% [2]. The Diabetes Prevention Program (DPP) achieved a 58% reduction in the incidence of diabetes through increased physical activity, dietary changes and weight loss [5]. The DPP involved intensive counseling and multiple in-person and group meetings, in a research context. Since then, numerous translations of the DPP have been developed, which attempt to provide approaches that can be widely applied.

Some adaptations of the DPP for real-world settings deliver the interventions through group meetings and in-person contact, such as those delivered in communities and YMCAs [6-8]. Ali et al. [9] found an average of 4.3% body weight loss in programs delivered by medical professionals, and 3.2% weight loss for those delivered by community members. While in-person and group-based interventions are important and effective resources, barriers to widespread adoption of such programs include lack of professional staff, institutional resources, substantial costs, and the requirement that participants attend a series of in-person meetings, which together substantially limit their scalability and reach [10, 11].

A number of interventions have combined some form of human coaching, at least by phone or email, with the use of technology, thus enabling them to achieve wider reach. In a meta-analysis of programs modeled on the Diabetes Prevention Program, Ali et al. found that among electronic-media-assisted programs, there was a statistically significant mean weight loss of 4% body weight [9]. A review by Levine et al. [12] of technology-assisted weight loss interventions in primary care found a mean weight loss in the intervention group of -2.7 kg among technology-assisted weight loss interventions that included some human coaching. Human feedback and coaching can provide value and effectiveness, and indeed is needed by some participants. However, it does result in higher costs that once again limit the number of persons with pre-diabetes that can be reached.

Fully automated behavioral intervention systems, those without any human coaching or facilitation, may hold substantial promise in overcoming barriers to wide-spread reach and adoption in a resource-limited healthcare environment, if they can be shown to be effective. Several such programs have been found to be effective for weight loss [13,
14], but there is very little information on the impact of such programs on glycemic markers critical for diabetes prevention. The Alive-PD intervention (Turnaround Health, a Division of NutritionQuest, Berkeley, CA., www.turnaroundhealth.com) provides such a fully automated, tailored online behavior-change program. Alive-PD is focused on reducing diabetes risk by reducing the biomarkers that constitute the criteria for diabetes, hemoglobin A1c (HbA1c) and fasting glucose, in persons at risk of developing diabetes. The purpose of this analysis is to examine the effects of this automated program on those glycemic biomarkers and weight loss, in a randomized controlled trial.

Methods

The Alive-PD Study was a randomized, wait-list controlled (usual care) trial among patients with clinical evidence of pre-diabetes. The primary outcome measures were changes in HbA1c and fasting glucose at the 6 month follow-up from baseline. Secondary outcomes were changes in body weight, body mass index (BMI), waist circumference, triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) ratio, a proxy measure for insulin resistance [15], and metabolic syndrome. Metabolic syndrome was defined as three or more of the five components (i.e., abdominal obesity, elevated blood pressure, elevated TG, low HDL, and dysglycemia) specified by the American Heart Association and the National Heart, Lung and Blood Institute [16]. The Framingham 8-year diabetes risk score was calculated [17]. Sample size was determined by using the estimated standard deviation (SD) of change in HbA1c from an intervention study on patients with diabetes [18]. With a SD of 1.4 and alpha of .05, we estimated that a final sample of 268 participants would provide 80% power to detect a minimum detectable difference in change in HbA1c of 0.48%. The goal for enrollment was 314 persons to achieve a sample size of 268, after 15% estimated attrition. The trial design and methods are described in detail elsewhere [19], and are summarized here. (See [19] for CONSORT flow diagram.)

Participant recruitment and eligibility criteria

Potential participants whose recent fasting glucose and/or HbA1c were within the pre-diabetes range were initially identified through an electronic health record query of patients in an ambulatory-care healthcare delivery system, the Palo Alto Medical Foundation (PAMF). The PAMF is a community-based multi-specialty group practice in Northern California (www.pamf.org). Patients meeting these criteria were recruited via letter, and underwent telephone screening for eligibility. Those meeting preliminary criteria were invited to attend a clinic visit to confirm eligibility, which also provided the baseline data for those confirmed eligible. At that visit, fasting glucose and lipids were measured by point-of-care whole blood testing using the Alere Cholestech LDX Analyzer. Similarly, HbA1c was measured using the Siemens DCA Vantage Analyzer. Biometric measurements, including height, body weight, waist circumference, and blood pressure were also obtained. BMI was calculated from height and body weight, and was expressed as kg/m².

Individuals were eligible if they were 30-69 years of age, with a BMI ≥27 kg/m², (BMI >25 kg/m² for Asian participants) [20], were English-speaking, were not taking diabetes medications, had access to email and internet, and had either fasting glucose or HbA1c in the pre-diabetes range (glucose 5.55-6.94 mmol/l [100-125 mg/dl], HbA1c 39-46 mmol/mol [5.7-6.4%]). If one measure reached the diabetic range and the other was pre-diabetic, the patient’s primary-care physician decided whether the patient had pre-diabetes and was eligible for the study. Additional exclusion criteria are described
The study was approved by independent Institutional Review Boards of Turnaround Health and PAMF.

After subjects provided signed informed consent, they were given brief (5-10 minutes) instruction that they were at risk for developing diabetes and that increased physical activity and changes in their dietary behaviors could help prevent progression to diabetes. PAMF research staff assisted participants in signing into an account for the Alive-PD web-based program, where participants provided their email address and password to the system. All subsequent communications with participants came from the electronic Alive-PD program and interactions with the Alive-PD program took place outside of the clinic.

Randomization
After leaving the study site, enrolled participants completed a brief questionnaire online, which provided information required for randomization. Randomization was conducted automatically, by computer algorithm, with stratification by sex, race/ethnicity (non-Hispanic White, other) and BMI ($< 35kg/m^2$, $\geq 35kg/m^2$), to achieve balance on those factors. Participants were randomized to start the intervention immediately (Intervention group) or after six months' delay (wait-listed usual-care group (Control group). Participants were notified of treatment group assignment by automated email from the Alive-PD system. The research and clinical staff at PAMF was masked to group assignment. Participants in the Control group received no further contact from the online Alive-PD system except reminders to complete a 3-month and 6-month online follow-up questionnaire. Because participants had consented only to a 6-month delay before they could start the intervention, only the 3-month and 6-month results constitute the randomized trial portion of the study.

The Alive-PD intervention
The program has been described in detail elsewhere [19]. Briefly, Alive-PD provides a one-year program of regular contact and goal-setting, weekly in the first six months and biweekly thereafter, plus mid-week automated email and smartphone reminders. The program includes individually-tailored weekly goal-setting and other activities delivered via web and email, supplemented by automated interactive voice response (IVR) phone calls and a supportive smartphone application. Alive-PD was developed with input from and was reviewed by diabetes educators, endocrinologists, registered dietitians, and psychological experts in health behavior change. All features and contacts are completely automated and algorithm-driven, with no personal contact or coaching either in-person or remotely. See Figure 1 and Online Appendix 2 for screenshots and other information.

[FIGURE 1 HERE]

The goal of the Alive-PD program is to improve glycemic control and reduce diabetes risk through lasting changes in physical activity and eating habits. Weight loss is encouraged and tracked as one of the changes that can reduce diabetes risk, although it is not the primary emphasis. For physical activity, participants set long-term goals of 150 to 300 minutes of aerobic activity per week, depending on reported levels at baseline and on subsequent program participation. Resistance training is encouraged as well. For eating behaviors, the focus is on decreasing added sugars and refined carbohydrates, decreasing saturated and trans fats, and increasing fruit and vegetables. Changes in food type and reduction in portion size are emphasized as a means of reducing energy
intake, rather than specific calorie targets or counting. Psychosocial issues important in
behavior change are addressed, including managing stress and sleep, staying
motivated, addressing negative thoughts, modifying one's environment to support
desired changes, and other topics addressed in the DPP curriculum [21].

These objectives are achieved through a system of weekly individually-tailored goal-
setting. Based on a detailed initial questionnaire on current dietary and activity habits,
and on the participant's subsequent interactions, the program recommends multiple
weekly personally-relevant small-step goals. Participants work on both increased
physical activity and improved dietary habits each week, as well as occasional
psychosocial goals. In addition to weekly personally-tailored goals, the system provides
tools for tracking of weight, eating and physical activity; weekly health information on
diabetes and strategies for preventing it; quizzes; social support through virtual teams
and a participant messaging system; feedback on reported diet and activity and on
success or failure of goal achievement; weekly reminders; and other features.
Engagement is promoted through a points system with modest monetary rewards, and
team competition. During the first six months, participants are reminded automatically if
they have not chosen a goal for two weeks, using data from the online system.

An email initiates the choice of weekly goals, provides a link to the participant's web
page, and generates a mid-week reminder. An Android and iPhone app also permits the
participant to select weekly goals, report on progress, and set smartphone reminders.
Automated motivational phone coaching is provided bi-weekly through Interactive Voice
Response technology (IVR), with interactions tailored to each individual's participation
status, barriers and primary motivations.

These strategies and features are based on established principles derived from several
bodies of behavior change research. The basic objective, derived from learning theory
and other habit formation research [22-24] is to have participants gradually incorporate
new eating and physical activity behaviors into their daily lives until these behaviors are
both habitual and substantial enough to reduce diabetes risk. To accomplish that
objective, a variety of strategies are employed to sustain involvement with the program
itself, and more importantly, to sustain the gradual incorporation of new, healthier
behaviors. The strategies are consistent with several bodies of research, including
models centering on cues and triggers [25, 26], social cognitive theory [27, 28], the
theory of planned behavior [29], behavioral economics [26, 30], and positive psychology
[31, 32]. For a more detailed description of the program, please refer to the published
protocol and program description [19].

**Subsequent clinic visits**
Participants in the Intervention and Control groups returned for clinic visits at three and
six months, at which time the laboratory and biometric measurements described above
were repeated by trained staff unaware of treatment assignment. Active monitoring of
adverse events was achieved by asking participants about sickness or injury at each
clinic visit. At the six-month visit, additional funding made it possible to invite participants
to continue the program for another six months, although the randomized trial segment
ended at six months. Those in the Intervention group continued in that arm. Those in the
Control group were transferred to the active Alive-PD intervention program, per the
original consent. Participants who consented to the extension were seen at additional
clinic visits at nine and twelve months.
Statistical methods
Intention-to-treat (ITT) analyses of change in HbA1c, fasting glucose and weight were pre-specified. Baseline characteristics were compared by chi-squared tests for categorical variables and t-tests for continuous variables. Mean between-group treatment differences in outcomes were evaluated by ITT analysis, using linear regression approaches. In all models, change in the outcome of interest (e.g., HbA1c) was the dependent variable, with treatment group the main predictor (independent) variable and baseline value of the outcome variable as a covariate. Missing values in the dependent variable were imputed using the approach of Heckman et al. [33, 34], in which variables need not be assumed to be missing at random (i.e., MAR). This approach corrects for the bias in estimates of change that may arise from participants failing to complete the follow-up clinic visits. We examined potential interactions with treatment group by variables that were expected a priori to be potential effect modifiers (sex, race/ethnicity, age, and BMI category) by inclusion of a cross-product term in the model. No significant interactions were found. Adjustment for age, sex, BMI and ethnicity did not materially alter the results. Dichotomous outcomes (e.g., achievement of 5% weight loss) were evaluated by chi-squared tests, after confirming the absence of interactions using logistic regression. For comparability with other studies, we also conducted subgroup analyses on participants who were pre-diabetic by HbA1c at baseline.

Results

Participant randomization and retention
A total of 340 participants met study eligibility criteria and were randomized. One participant randomized to the Intervention group developed a metabolic condition rendering glycemic markers uninterpretable and was excluded from analysis, leaving 339 randomized subjects.

Study retention and participation in biometric assessment visits was high; 89% (302/339) completed the 3-month follow-up assessment, and 86% (292/339) completed the 6-month follow-up assessment. Of the 47 study participants that did not complete the 6-month follow-up (20 Control, 27 Intervention), 9 were lost to follow-up and 38 withdrew from the study. Reported adverse events were minor and all were considered to be unrelated to study participation. There were no significant differences in adverse events between treatment groups at either the 3-month or 6-month visit (data not shown). One participant in the Control group was diagnosed with diabetes and withdrew from the study; this participant did not provide follow-up measurements, but was included in the ITT analysis. No participants were prescribed metformin or other diabetes medications during the study.

Baseline characteristics
Participants were on average 55 years of age (range 31-70), with a mean BMI of 31.1 kg/m² (Table 1). The majority, 69% (233/339), were male. Mean fasting glucose was at the low end of the pre-diabetic range (6.1 mmol/l [109.9 mg/dl, SD 8.4 mg/dl]), and mean HbA1c was in the normal range (5.6% [38 mmol/l, SD 3.2]). Metabolic syndrome was present in 68.1% of participants (231/339). The study cohort was well-educated, 83% (281/339) having a college degree or higher. The Framingham 8-year diabetes risk was 16.6% at baseline in both groups. The Intervention and Control groups were well balanced on baseline characteristics, although there was some imbalance for
This imbalance was due largely to a difference in Hispanic ethnicity (8% vs. 4.3%; \( P = .04 \)). Due to this imbalance, race/ethnicity was examined for confounding and effect modification in all models.
<table>
<thead>
<tr>
<th>Variable</th>
<th>Category</th>
<th>All</th>
<th>Control</th>
<th>Intervention</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N = 339</td>
<td>N = 176</td>
<td>N = 163</td>
<td></td>
</tr>
<tr>
<td>Age, years, mean (SD)</td>
<td></td>
<td>55.0 ± 8.9</td>
<td>54.9 (9.1)</td>
<td>55.0 (8.8)</td>
<td>.88</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td></td>
<td>106 (31.3)</td>
<td>54 (30.7)</td>
<td>52 (31.9)</td>
<td>.81</td>
</tr>
<tr>
<td>College or above, n (%)</td>
<td></td>
<td>281 (82.9)</td>
<td>144 (81.8)</td>
<td>137 (84.1)</td>
<td>.59</td>
</tr>
<tr>
<td>Race/ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.07</td>
</tr>
<tr>
<td></td>
<td>White</td>
<td>229 (67.6)</td>
<td>120 (68.2)</td>
<td>109 (66.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hispanic</td>
<td>21 (6.2)</td>
<td>14 (8.0)</td>
<td>7 (4.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asian</td>
<td>70 (20.6)</td>
<td>29 (16.5)</td>
<td>41 (25.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>19 (5.6)</td>
<td>13 (7.4)</td>
<td>6 (3.7)</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome, n (%)</td>
<td></td>
<td>231 (68.1)</td>
<td>121 (68.8)</td>
<td>110 (67.5)</td>
<td>.80</td>
</tr>
<tr>
<td>Weight, kg, mean (SD)</td>
<td></td>
<td>92.9 (15.8)</td>
<td>93.3 (16.6)</td>
<td>93.7 (14.9)</td>
<td>.68</td>
</tr>
<tr>
<td>BMI, k/m², mean (SD)</td>
<td></td>
<td>31.2 (4.4)</td>
<td>31.2 (4.3)</td>
<td>31.1 (4.5)</td>
<td>.73</td>
</tr>
<tr>
<td>Waist circumference, cm, mean (SD)</td>
<td></td>
<td>102.8 (10.8)</td>
<td>103.1 (11.2)</td>
<td>102.5 (10.4)</td>
<td>.62</td>
</tr>
<tr>
<td>Glucose, mmol/l, mean (SD)</td>
<td></td>
<td>6.10 (0.5)</td>
<td>6.08 (0.5)</td>
<td>6.11 (0.5)</td>
<td>.57</td>
</tr>
<tr>
<td>Glucose, mg/dl, mean (SD)</td>
<td></td>
<td>109.9 (8.4)</td>
<td>109.6 (8.3)</td>
<td>110.1 (8.6)</td>
<td>.57</td>
</tr>
<tr>
<td>HbA1c, %, mean (SD)</td>
<td></td>
<td>5.6 (0.3)</td>
<td>5.6 (0.3)</td>
<td>5.6 (0.3)</td>
<td>.90</td>
</tr>
<tr>
<td>HbA1c, mmol/l, mean (SD)</td>
<td></td>
<td>38.2 (3.2)</td>
<td>38.2 (3.1)</td>
<td>38.1 (3.3)</td>
<td>.90</td>
</tr>
<tr>
<td>Total cholesterol, mmol/l, mean (SD)</td>
<td></td>
<td>5.0 (0.8)</td>
<td>5.0 (0.9)</td>
<td>4.9 (0.8)</td>
<td>.82</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/l, mean (SD)</td>
<td></td>
<td>3.0 (0.7)</td>
<td>3.0 (0.7)</td>
<td>3.0 (0.7)</td>
<td>.73</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/l, mean (SD)</td>
<td></td>
<td>1.2 (0.4)</td>
<td>1.2 (0.3)</td>
<td>1.2 (0.4)</td>
<td>.34</td>
</tr>
<tr>
<td>Triglycerides, mmol/l, mean (SD)</td>
<td></td>
<td>1.6 (0.8)</td>
<td>1.7 (0.8)</td>
<td>1.6 (0.9)</td>
<td>.54</td>
</tr>
<tr>
<td>TG/HDL ratio, mean (SD)</td>
<td></td>
<td>3.5 (2.5)</td>
<td>3.6 (2.5)</td>
<td>3.4 (2.5)</td>
<td>.41</td>
</tr>
<tr>
<td>Blood Pressure, mmHg, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td></td>
<td>130.4 (14.7)</td>
<td>130.4 (14.5)</td>
<td>130.5 (15.0)</td>
<td>.95</td>
</tr>
<tr>
<td>Diastolic</td>
<td></td>
<td>82.3 (8.4)</td>
<td>82.6 (8.7)</td>
<td>82.0 (8.1)</td>
<td>.51</td>
</tr>
</tbody>
</table>
**Primary outcomes**

Significant decreases in HbA1c and fasting glucose were observed in the Intervention group by three months from baseline, and declined further at 6-months (Figure 2, A and B).

In ITT analyses, which included all 339 participants, mean reductions (95% CI) in fasting glucose at six months from baseline were significantly greater in the Intervention group (-0.41 mmol/l [-0.44, -0.12]) than in the Control group (-0.21 mmol/l [-0.15, -0.10]; \( P < .0001 \)) (Table 2). Mean reductions in HbA1c were also significantly greater in the Intervention vs. the Control group (-0.26% [-0.27, -0.24] vs. -0.18% [-0.19, -16]; \( P = .0006 \)). No effect modification by race/ethnicity, age, sex, or BMI category was observed.

### Table 2. Change in clinical outcomes, by treatment group

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-diabetic by HbA1c&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Pre-diabetic by HbA1c&lt;sup&gt;c&lt;/sup&gt;</th>
<th>( P &lt;sup&gt;b&lt;/sup&gt; )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alive-PD N=60</td>
<td>Control N=69</td>
<td></td>
</tr>
<tr>
<td>Fasting glucose, mg/dl</td>
<td>-7.38</td>
<td>-1.23</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>95% CI</td>
<td>(-9.40, -5.36)</td>
<td>(-3.12, +0.65)</td>
<td></td>
</tr>
<tr>
<td>Change</td>
<td>-7.36</td>
<td>-2.19</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>95% CI</td>
<td>(-7.85, -6.87)</td>
<td>(-2.64, -1.73)</td>
<td></td>
</tr>
<tr>
<td>Metric</td>
<td>Change</td>
<td>95% CI</td>
<td>P</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------</td>
<td>--------------</td>
<td>-------</td>
</tr>
<tr>
<td>Fasting glucose, mmol/l</td>
<td>-0.41</td>
<td>(-0.44, -0.38)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>-0.26</td>
<td>(-0.27, -0.24)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>HbA1c, mmol/mol</td>
<td>-2.81</td>
<td>(-2.95, -2.66)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>-3.26</td>
<td>(-3.26, -3.25)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>Weight loss, %</td>
<td>-3.60</td>
<td>(-3.63, -3.57)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>-1.05</td>
<td>(-1.06, -1.05)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>Waist, cm</td>
<td>-4.56</td>
<td>(-4.69, -4.43)</td>
<td>&lt;.00 1</td>
</tr>
<tr>
<td>TG/HDL ratio</td>
<td>-0.21</td>
<td>(-0.30, -0.12)</td>
<td>.04</td>
</tr>
</tbody>
</table>

a Imputation of missing dependent variables using Heckman/QLIM  
b Significance of difference in changes between the two groups  
c Subjects pre-diabetic by HbA1c at baseline and providing complete data  
d 95% confidence limits from least squares means from models of following form: Change=baseline + treatment Group.

While all participants had pre-diabetes at baseline by either HbA1c or fasting glucose, only 45% had pre-diabetes based on HbA1c. In a subgroup analysis among those with pre-diabetes at baseline by HbA1c (Table 2, "Pre-diabetic by HbA1c"), the mean reduction (95% CI) in HbA1c was greater than in the Intervention group as a whole (-0.32% [-0.38, -0.26]), and was significantly greater relative to the Control group (-0.20% [-0.25, -0.15], P = .0015).
Secondary outcomes

In the ITT analysis, reduction in weight, BMI, waist circumference and TG:HDL ratio were all significantly greater in the Intervention group than the Control group (Table 2). The Intervention group lost on average 3.26 kg (95% CI: -3.26, -3.25), compared with 1.26 kg (95% CI: -1.27, -1.26) in the Control group, (P<.0001). BMI was reduced on average by 1.05 kg/m$^2$ (95% CI: -1.06, -1.05) and 0.39 kg/m$^2$ (95% CI: -0.39, -0.38) in the Intervention and Control groups respectively (P<.0001). The mean reduction in waist circumference in the Intervention group was 4.56 cm (95% CI: -4.69, -4.43) as compared to 2.22 cm (95% CI: -2.36, -2.09) in the Control group (P = .0009). In addition, the ratio of TG:HDL was significantly more reduced in the Intervention group relative to the Control group (-0.21 [-0.30, -0.12] vs. +0.21 [95% CI: 0.12, 0.29]; P=.04).

The proportion of participants, by treatment group, meeting specific thresholds are shown in Figure 3. At six months, 35% of the Intervention group had achieved at least a 5% weight loss compared to 8% of Controls (Figure 3A). Among those who were pre-diabetic by fasting glucose at baseline, 40% of Intervention subjects had achieved a normal fasting glucose, compared to 17% of Controls (Figure 3B). Among participants who had metabolic syndrome at baseline, 47% of those in the Intervention group no longer had metabolic syndrome at six months, compared with 20% of Controls (Figure 3C). BMI was reduced by at least one unit in 45% of Intervention participants compared with 19% of Control participants (Figure 3D). All these differences between the Intervention and Control group were significant at P<.001.

[FIGURE 3 HERE]

There was a significantly greater reduction in Framingham 8-year diabetes risk in Intervention than in Control (P=.0004) in the intention-to-treat sample (Figure 4). In both groups the baseline diabetes risk was 16%. At 6 months, it was 11.00% (CI 10.08, 11.92) in the Intervention group, and 14.59% (CI 13.64, 15.54) in the Control group.

[FIGURE 4 HERE]

Case report on subjects in the diabetic range by fasting glucose

Alive-PD was designed to assist persons with pre-diabetes. However, lifestyle behavior change is also an essential intervention for persons who are newly diagnosed with diabetes. Thus, information about results in the eight participants in our sample who had a fasting glucose in the diabetes range at baseline is of interest. (These participants were all cleared by their physicians for participation in the study.) Of the five in the Intervention group, one had a decrease in fasting glucose to the normal range (<100mg/dl), and the other four had a decrease in fasting glucose to the pre-diabetic range (<126 mg/dl) after the 6-month intervention period. None of the three participants in the Control group had decreases in glucose out of the diabetic range.

Process measures and other behaviors

We assessed program participation by evaluating the points each participant earned through interacting with the program components each week, and by assessing the participants’ weekly goal setting behaviors. Participation in the online Alive-PD program features was high. Intervention participants (ITT population, N = 163) set behavioral goals or otherwise interacted with the online Alive-PD program in a median of 17 of the 24 weeks (71% of the weeks). Eighty-seven percent interacted with the program in four or more of the 24 weeks, and 71% were still interacting with the program in the last month of the six-month period. Participants accomplished a median of 37 goals in the
A 24-week period or about 1.5 goals per week. Intervention participants reported that they spent about 15 minutes interacting with the program in a typical week.

The Intervention group experienced significant improvements in self-reported physical activity, dietary habits, sleep, fatigue, and self-confidence relative to the Control group ($P<.001$) (data not shown). A more detailed analysis of changes in physical activity, diet, self-confidence and other psychosocial factors will be reported elsewhere.

**Discussion**

In this randomized controlled trial, the fully-automated Alive-PD program was effective in improving glycemic control and body weight, and in reducing 8-year diabetes risk. In ITT analyses, the Intervention group achieved reductions in fasting glucose of -41 mmol/l [-7.36 mg/dl] and in HbA1c of -0.26% [-3 mmol/mol]), both statistically significantly superior to changes in the Control group. In addition, Intervention group participants lost an average of 3.26 kg over 6 months, in ITT analyses, and 35% of the Intervention group lost 5% or more of initial body weight, both significantly superior to the Control group.

**Previous research on weight loss in diabetes prevention or weight loss programs**

Numerous reviews of weight loss or translational diabetes prevention programs have been conducted [9, 12, 35-42], covering a range of delivery methods. Interventions using in-person or group approaches have achieved average weight losses of approximately 3-4% in reviews and meta-analyses [9, 37], although some individual studies have reached weight losses of >6% in the intervention group [6, 43].

For wider reach, however, many interventions have combined coaches with some form of technology. In a 2015 review of 16 studies of technology-assisted programs for weight loss in primary care, Levine et al. [12] found a median weight loss of -2.7 kg in intervention groups of 12 programs that combined human with technological methods. Ali et al. [9] found an average loss of 4.2% of body weight in electronic media-assisted programs.

Interventions delivered entirely by electronic media, primarily for weight loss, have also been reviewed. Hartmann-Boyce et al. conducted a meta-analysis of 23 randomized trials of “self-help interventions” for weight loss in overweight or obese adults [13]. Programs were not eligible for inclusion if they used any form of person-to-person assistance by counselors or health professionals. The analysis found a mean difference between intervention and comparison groups of -1.85 kg at 6 months (CI -2.86, -0.83). Three programs using eHealth technologies that were not included in the Hartmann-Boyce review were found by Hutchesson et al. [14] to have a mean difference of -1.5 kg. Three other fully-automated studies from the Levine review [12] found a mean weight loss in the intervention group of 2.5 kg. One recent trial not included in previous reviews [44] was fully automated with the exception of a 60-minute baseline visit at which participants were given weight loss, calorie and physical activity goals, and taught behavioral skills. A weight loss of 5.4 kg was observed at 6 months.

The effect of internet-based interventions on change in waist circumference has also been examined in a meta-analysis [45]. Seo and Niu found a mean change of -2.99 cm (C.I. -3.68 to –2.30 cm).
Previous research on the effect of fully-automated programs on glycemic markers
With few exceptions, most studies of diabetes prevention or weight loss interventions have not measured or reported on changes in glycemic markers. One review found “minimal” changes in glycemic markers across the reviewed studies, with a median change in fasting glucose -0.2 mmol/l [37], and another found mean change of -0.1 mmol/l [38]. For HbA1c, Dunkley et al. [38] found pooled changes of -0.13% and Johnson et al. found median change of -0.05%.

The treatment effects for Turnaround Health’s Alive-PD program are consistent with and in most cases somewhat larger than the results summarized in meta-analyses above. This is true for weight loss (-3.26 kg), percent weight loss (-3.60%), waist circumference (-4.56 cm), and the glycemic markers HbA1c (-0.26%) and fasting glucose (-0.41 mmol/l), in intention-to-treat analyses.

The Diabetes Prevention Recognition Program
The CDC Diabetes Prevention Recognition Program (DPRP) is intended to recognize organizations that have demonstrated their ability to deliver a proven type 2 diabetes prevention lifestyle intervention [46]. CDC recently updated the requirements for recognition to include programs delivered “virtually”, provided they meet other criteria. Turnaround Health’s Alive-PD program is listed on the CDC website [47]. As of August 1, 2015, it is the only such program with evidence of effectiveness from a randomized controlled trial and the only study with intention-to-treat analysis.

Features promoting effectiveness
A number of authors have attempted to identify or summarize what features of a behavioral intervention may be associated with its effectiveness [40, 42, 48]. The following have all been identified as contributors to effectiveness: goal-setting; self-monitoring; tailoring and tailored feedback; reminders; social support; and a structured program employing behavior-change principles. Khaylis et al.[48] also listed feedback by a counselor as an important feature, but noted that computer-automated email feedback has been as effective as human email counseling in at least one study. With the exception of human counseling, all of these features are incorporated into the Alive-PD program. In addition, Alive-PD added some gamification features, such as a points system, team competition, and monetary rewards, to enhance engagement and retention.

Research is under way to explore which features of Alive-PD may have been more important or beneficial. While all participants were exposed to all of these components (goal-setting, messaging, etc.), different participants engaged in them to different extents. For example, 39% (63/163) never logged their weight or physical activity, while 12% (20/163) logged their weight or activity in 21 or more of the 24 weeks. Mediation analyses are under way. However, it is worth noting that participants are individuals with varying interests and motivations. Some people appreciate being on a team while others dislike it, and the same can be said of other components. Alive-PD was intentionally designed to provide an array of components so as to engage the widest range of different interests, learning styles and available time.

In addition to the potential role of features of an intervention, it is also of considerable interest to explore what behaviors and specific changes contributed to the study
outcomes. Recent literature has discussed the relative roles of types of macronutrients (fats vs. carbohydrates), physical activity and weight loss [49-51]. The Alive-PD program promoted, and achieved, increases in physical activity, reductions in refined carbohydrates, reductions in saturated and trans fats, and increases in fruits and vegetables. Changes in specific foods were also encouraged, such as nuts, legumes and olive oil. Participants in the Intervention group undertook these changes to varying degrees. In future analyses we will examine the effect of these variations on changes in glycemic markers and weight. For example, there was a significant reduction in HbA1c, even among those who did not achieve 5% weight loss. We plan to explore factors that contributed to glycemic improvements in the absence of major weight loss.

**Limitations**
The fully automated nature of the Alive-PD program is both a strength and a limitation. Some people need and respond better to human interaction and support, and effect sizes might be greater if combined with human support. In addition, because the intervention is delivered by email, internet and smartphone, it may have limited reach for those who do not have internet access or who are not technologically proficient. While its reach is somewhat limited in that respect, as of 2014 87% of American adults used the Internet, including over 80% of African Americans and Hispanics [52]. These technologies are nearly ubiquitous in society and allow for convenient program access at home or through mobile devices. At the same time, the fully-automated characteristic of the program is beneficial for several reasons. There is a guarantee of 100% fidelity to the design and content in future administrations, and enhancements can be readily incorporated. Because it is fully automated, this commercial program can be delivered at low cost and with wide reach. Additionally, organizations using it would require no or minimal staff.

Although the Alive-PD program provides a one-year intervention, the randomized trial analysis was for only a six-month period. This was due to initial funding limitations, as well as to the desire to enhance enrollment of these persons at high risk of developing diabetes by assuring them that they would be given access to the active program in a reasonable period of time. It will be important to follow study participants for a full year, to determine whether the trends seen in Figure 2 are maintained.

Study participants were relatively well-educated and two-thirds were non-Hispanic white. Thus, the generalizability to less educated individuals and those of race/ethnic minority groups remains to be investigated. However, it is notable that the subgroup with post-graduate or professional degrees achieved less improvement in glycemic markers than those with lower educational levels (data not shown.) The sample did include a substantial number of Asians (21% of the study cohort), including South Asians, a group for which Type 2 diabetes is especially common. Although analyses indicated no significant differences in treatment effects by ethnicity, more research is needed to confirm effectiveness in minority groups.

**Clinical relevance**
The decrease in fasting glucose in the Intervention group (-7.36 mg/dl, [in SI units -0.41 mmol/l]) was clinically meaningful and substantial. The decrease in HbA1c was modest (-0.26% [-2.81 mmol/mol] in the ITT analysis and -0.32% [-3.5 mmol/mol] in those pre-diabetic by HbA1c), but significantly greater than in Controls. We note that baseline levels of HbA1c were low in the study cohort. Indeed, mean HbA1c at baseline was in the normal range, and only 45% were pre-diabetic by HbA1c. As a result, the magnitude
of the average treatment effect was not as large as might be expected in patients with higher values in the pre-diabetic range or in those with diabetes. Weight loss was 4% of baseline weight among those pre-diabetic by HbA1c (Table 2), and increased with increasing participation in the program and higher baseline weight (data not shown). As noted, the primary objective was to lower glycemic markers, a direct measure of reduced diabetes risk, and this appears to have been achieved despite the relatively modest weight loss. The Intervention group decreases in HbA1c and fasting glucose were greater than those seen in the DPP Lifestyle group at 6 months (HbA1c -0.26% vs. -0.09%; fasting glucose -7.36 mg/dl vs. 4.59 mg/dl respectively), despite the fact that the Intervention Group's weight loss was not as great as that seen in DPP (3.26 kg vs. -6.5 kg) [5].

More than two-thirds of enrollees were male, a different sex distribution than is usually seen in health interventions. (The DPP had 68% female participants.) [5] The electronic format may have had more appeal for men than a series of group or personal interactions. There was not a significant interaction between sex and treatment effect, and treatment effects were not significantly different by sex for HbA1c, fasting glucose or weight.

Summary
In summary, Alive-PD was effective in improving markers of glycemic control and body weight in patients with pre-diabetes. As noted by Cefalu et al. [4], the driving force behind the increased economic burden of diabetes is increased prevalence. Therefore, engaging as many as possible of the nation's 86 million adults with pre-diabetes with a variety of cost-effective interventions is an urgent priority. Effective, fully automated technologies such as Alive-PD represent one of those strategies, with the potential of serving large numbers of persons at risk of progression to diabetes.

Acknowledgements

Author contributions: G.B. designed and led the study. K.A. was principal investigator of the PAMFRI sub-award for the clinical component, and R.J.R. was co-investigator of the sub-award. G.B., K.A. and R.J.R. co-wrote the manuscript, and T.J.B., C.H.B., L.P. and M.D. contributed to the writing of the manuscript. T.J.B., G.B., C.H.B and H.A.C. designed and implemented the Alive-PD program. D.H. conducted and led the systems engineering. G.B. and R.J.R. conducted the analyses, and M.L.H. reviewed the analyses. M.D. researched data and contributed to program implementation.

Conflicts of Interest


Funding: Research reported in this publication was supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number R44NR012617. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
18
38. Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C. Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact...
47. Centers for Disease Control and Prevention DPRP. Registry of Recognized Programs, Virtual, Online or Combination of In-person/Online Programs. 2015. https://nccd.cdc.gov/DDT_DPRP/Registry.aspx. Archived at: http://www.webcitation.org/6aXdCnzHn
Figure 2. Changes in primary and secondary endpoints over time. Solid line: control; dashed line: intervention; error bars: ± standard error. A: Change in HbA1c. B: Change in fasting glucose. C: Change in waist circumference. D: Change in weight. At 6 months, all measures were significantly different between control and intervention groups (P<.001).
Figure 3. Proportion achieving secondary endpoint thresholds at 6 months. Error bars not shown because all differences between control and intervention were \( P<.001 \). A: Percentage with \( \geq 5\% \) weight loss (complete data: \( n=156 \) control, \( n=136 \) intervention). B: Percentage who moved to normal fasting glucose (from \( \geq 100 \text{ mg/dL} \) to \( <100 \text{ mg/dL} \)) (denominator: \( n=150 \) control, \( n=126 \) intervention). C: Percentage who moved from having metabolic syndrome to not having metabolic syndrome (denominator: \( n=110 \) control, \( n=86 \) intervention). D: Percentage whose BMI decreased by 1 kg/m\(^2\) (denominator: \( n=156 \) control, \( n=136 \) intervention).
Figure 4. Change in Framingham 8-year diabetes risk.